Farnesyltransferase inhibitor 277 (FTI-277) has been used to:
inhibit protein farnesylation in breast cell lines.[1]
in marrow-isolated adult multilineage inducible cells (MIAMI).[2]
inhibition of farnesyl transferase in CV-1 in Origin with SV40 genes cells (COS-7).[3]
Biochem/physiol Actions
Farnesyltransferase inhibitor 277 (FTI-277) mediates apoptosis in multiple myeloma and is regarded as a potential therapeutic agent.[4]
Highly potent (pM/nM) Ras CAAX peptidomimetic which antagonizes both H and K-Ras oncogenic signaling. Inhibitor of farnesyltransferase (Ftase) IC50 = 50 nM.
Packaging
Very hygroscopic material, package in a dry room with deoxygenated MeOH and pump down the solvent. Store with desiccant.
Biochemical and biophysical research communications, 556, 93-98 (2021-04-13)
Sepsis remains a leading cause of mortality in critically ill patients and is characterized by multi-organ dysfunction. Mitochondrial damage has been proposed to be involved in the pathophysiology of sepsis. In addition to metabolic impairments resulting from mitochondrial dysfunction, mitochondrial
Molecular therapy : the journal of the American Society of Gene Therapy, 30(2), 672-687 (2021-07-19)
Triple-negative breast cancer (TNBC) has a high propensity for organ-specific metastasis. However, the underlying mechanisms are not well understood. Here we show that the primary TNBC tumor-derived C-X-C motif chemokines 1/2/8 (CXCL1/2/8) stimulate lung-resident fibroblasts to produce the C-C motif
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
